CATALYSTYahoo Finance • 22h ago
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong BuyYahoo Finance report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
Why MRKR Stock dropped -8.05% Today — RQD Quant Desk Flash
$0.90 -8.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.89
Marker Therapeutics Inc. (MRKR) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $16.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MRKR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MRKR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Marker Therapeutics Inc. (NASDAQ: MRKR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.90 (-8.05% 1D, market cap $16.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MRKR ranks #610 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MRKR compare to AEON and NEUP in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRKR carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AEON (AEON Biopharma Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -11.8%, cap $16.5M). Among the 5-stock peer group, MRKR leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MRKR?
▼
Per MRKR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001094038), Marker Therapeutics Inc. generated $36.1M in revenue (+15.9% YoY), -$12.2M in net income, and -$12.0M in free cash flow against $19.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.89 (-1.64%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MRKR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY MRKR SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (23% of score)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 45 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.92+26.1% Next Q
43
Q2 (-2Q)Grade D$1.16-18.1% Next Q
40
Q3 (-1Q)Grade E$0.95-5.3% Next Q
38
CurrentGrade D-$0.90-8.5% Hist 90D α
35
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MRKR Turnaround Squeeze
While MRKR currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.13) and Max Pain ($0.95) forces dealer call-delta covering toward $2.58.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MRKR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MRKR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MRKR Stock dropped -8.05% Today — RQD Quant Desk Flash
Marker Therapeutics Inc. (MRKR) dropped -8.05% to $0.90, trading at 4% of its 52-week range ($0.84 – $2.46). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($0.84 – $2.46) with RSI-14 at 45 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.90 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live MRKR Headlines & Catalysts
MARKET WIREStockInvest.us • 1d ago
Marker Therapeutics Stock Price Forecast. Should You Buy MRKR?StockInvest.us report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREZacks Investment Research • 1d ago
MRKR: MARKER THERAPEUTICS - Price & Consenus ChartZacks Investment Research report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session - Marker Therapeutics (NASDAQ:MRKR), Alaunos ThBenzinga report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Marker Therapeutics, Inc. Stock Price Today | MRKR Live Chart & NewsTraders Union report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESyfe • 1d ago
Marker Therapeutics, Inc. (MRKR) Stock Price & NewsSyfe report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
MRKR Q3'26 Earnings: revenue estimate is 2.12M USDTradingView report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Marker Therapeutics Awarded $2.6 Million FDA OrphanGlobeNewswire report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 15d ago
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic CancerCompetitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platformHOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therap
RISK WATCHBenzinga • 15d ago
Marker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic CancerMarker Therapeutics, Inc. (NASDAQ:MRKR), is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MRKR)
- ✓Walkthrough of MRKR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MRKR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.31%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.01H $1.01L $0.90C $0.90VOL 67.6K
RES: $1.43SUP: $0.82SMA50: $1.13SMA200: $1.36
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MRKR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +15.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on MRKR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MRKR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MRKR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MRKR)
Health Care Rank #610 of 1015
⚔️ AEON vs MRKR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MRKR vs. AEON, NEUP, RADX, PBM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Marker Therapeutics Inc. (MRKR) ranks #610 by composite RQD confidence (35/100, grade D-) and #844 by equity capitalization ($16.3M). Within this direct 5-issuer industry benchmark cohort, MRKR leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. AEON currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MRKR at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MRKR
ACTIVE
Marker Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -8.05% | $16.3M | Benchmark Subject |
| AEON AEON Biopharma Inc. (Class A) | D | 46/100 | — | — | -35.0% | -0.36% | $16.2M | /aeon-vs-mrkr → |
| NEUP Neuphoria Therapeutics Inc. | E | 31/100 | — | — | -11.8% | -0.33% | $16.5M | /neup-vs-mrkr → |
| RADX Radiopharm Theranostics Limited | D | 46/100 | — | — | — | -8.05% | $15.6M | /radx-vs-mrkr → |
| PBM Psyence Biomedical Ltd. | D | 46/100 | — | — | — | -3.93% | $17.6M | /pbm-vs-mrkr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001094038 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Marker Therapeutics Inc. (MRKR) reported GAAP revenue of $36.1M (+15.9% vs. FY2024 revenue of $31.1M , and -11.6% cumulative change since FY2023) , GAAP net income of -$12.2M, operating cash flow of -$12.0M, and free cash flow of -$12.0M (-10.1% YoY). On the balance sheet, MRKR closed FY2025 with $19.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $36.1M | -$12.2M | -$12.0M | -$12.0M | $19.1M | — |
| FY2024 (FY) | 2024-12-31 | $31.1M | -$10.7M | -$10.9M | -$10.9M | $22.0M | — |
| FY2023 (FY) | 2023-12-31 | $40.8M | -$8.2M | -$16.4M | -$16.4M | — | — |
3. MRKR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MRKR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Marker Therapeutics Inc. (NASDAQ: MRKR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.90 (-8.05% 1D, market cap $16.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MRKR ranks #610 in composite RQD confidence.
How does MRKR compare to AEON and NEUP in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRKR carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AEON (AEON Biopharma Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.2M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -11.8%, cap $16.5M). Among the 5-stock peer group, MRKR leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MRKR?
Per MRKR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001094038), Marker Therapeutics Inc. generated $36.1M in revenue (+15.9% YoY), -$12.2M in net income, and -$12.0M in free cash flow against $19.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MRKR trading relative to its 50-day, 200-day, and 52-week technical levels?
MRKR last traded at $0.90 (-8.05% on volume of 265,722 shares), positioning the stock -20.35% below its 50-day simple moving average ($1.13) and -33.82% below its 200-day simple moving average ($1.36). Across its 52-week range of $0.84 to $2.46, MRKR sits at the 3.7% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.01).
ROARABLE RATING BRIEF • RQD 35/100 (D-)
✓ SEC XBRL & RQD VERIFIED
MRKR — Marker Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Marker Therapeutics Inc. (MRKR) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.90 (-8.05% 1D, market capitalization $16.3M).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Marker Therapeutics Inc. (MRKR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It is a biotechnology company. Specific products, customers, and revenue model details are — Reported revenue across the financial periods is —.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Marker Therapeutics Inc. (MRKR) reported $36.1M in annual revenue (up from $31.1M in FY2024, +15.9% YoY) and -$12.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($40.8M revenue, -$8.2M net income) through FY2025, MRKR scaled operating cash flow to -$12.0M and free cash flow to -$12.0M, backed by $19.1M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.84 – $2.46 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MRKR carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can MRKR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $36.1M and free cash flow of -$12.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is MRKR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
MRKR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Marker Therapeutics Inc. (MRKR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 22h ago
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy Yahoo Finance report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 1d ago
Marker Therapeutics Stock Price Forecast. Should You Buy MRKR? StockInvest.us report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Zacks Investment Research • 1d ago
MRKR: MARKER THERAPEUTICS - Price & Consenus Chart Zacks Investment Research report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session - Marker Therapeutics (NASDAQ:MRKR), Alaunos Th Benzinga report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Marker Therapeutics, Inc. Stock Price Today | MRKR Live Chart & News Traders Union report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Syfe • 1d ago
Marker Therapeutics, Inc. (MRKR) Stock Price & News Syfe report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
MRKR Q3'26 Earnings: revenue estimate is 2.12M USD TradingView report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Marker Therapeutics Awarded $2.6 Million FDA Orphan GlobeNewswire report covering Marker Therapeutics Inc. (MRKR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MRKR Bull vs. Bear Conversation Board — What's Your Call at $0.90?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MRKR 🐻 33% BEARISH CONVICTION
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH
🎯 Target: $1.27 (+29.6%)
📌 Pinned Debate Market-wire coverage includes a rating-upgrade headline to Strong Buy, and the stock trades near its 52-week low at $1.01 versus a $2.4
Here is why I am bullish on MRKR here at $0.98: Market-wire coverage includes a rating-upgrade headline to Strong Buy, and the stock trades near its 52-week low at $1.01 versus a $2.46 high.. Compare MRKR's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $0.93 are getting bought.
EarningsSniper 🐂 BULL
@SkepticalCFA Shorting a 5/20 institutional whale-flow stock at $0.98 is dangerous when funds are rotating into Health Care.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $0.73 (-25.5%)
Spot @ $0.98 With zero revenue, a -35% ROIC, a Piotroski F-Score of 2/9, and cash falling from $19.2M to $16.1M, the company shows no visible path t
Careful chasing MRKR at $0.98. With zero revenue, a -35% ROIC, a Piotroski F-Score of 2/9, and cash falling from $19.2M to $16.1M, the company shows no visible path to self-funded operations.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.73 on multiple compression.